PLX (Protalix BioTherapeutics Inc. (DE)) stock: $2.54, $204.7M market cap, $40.7M cash, $164.0M EV, $204.7M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
What they do
We are a commercial stage biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Global rights to market/sell licensed to Pfizer ex-Brazil (drug substance supplied by company through 2030); Brazil commercialization via Fiocruz/BioManguinhos (therapy of choice for newly diagnosed Gaucher patients per Brazilian MoH guidelines).
Indications
Gaucher disease (adults and children ≥4 years)(Approved)
Status note Plant cell-expressed recombinant glucocerebrosidase approved in the U.S., Brazil, Israel and other jurisdictions for Gaucher disease. Company holds worldwide rights outside the Pfizer (global ex-Brazil) and Fiocruz (Brazil) arrangements.
Partnerships Commercialized worldwide by Chiesi Farmaceutici under exclusive U.S. and ex-U.S. license/supply agreements; company supplies drug product and receives 15-40% of net sales. $25M milestone received Mar 31, 2026 following EU E4W approval; up to $740M (U.S.) and $270M (ex-U.S.) additional milestones. Kwang Dong Pharm. is Chiesi's distributor/MOH-holder in South Korea.
Indications
Fabry disease (adults)(Approved)
Status note PEGylated recombinant human alpha-galactosidase A for Fabry disease; approved in the U.S. (with a boxed warning) and EU. Mar 2026 EU approval of a 2 mg/kg every-4-weeks (E4W) dosage in addition to the 1 mg/kg every-2-weeks dosage; South Korea orphan marketing authorization granted May 2026. U.S. Patent No. 9,194,011 term extended to Nov 17, 2035.
PRX-119
Preclinical · ActiveModality: PEGylated recombinant human DNase I (plant cell-expressed)
Target extracellular DNA (NETs)
Partnerships Company holds worldwide commercialization rights.
Status note Plant cell-expressed PEGylated recombinant human DNase I candidate for long and customized systemic circulation for NETs-related diseases. Early-stage; company turning focus to new early-stage candidates in indications with high unmet need, including renal diseases.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.